Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease - PubMed (original) (raw)
Review
. 2005 Jan;11(1):RA17-23.
Affiliations
- PMID: 15614202
Review
Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease
Yu Watanabe et al. Med Sci Monit. 2005 Jan.
Abstract
Parkinson's disease is one of the major neurodegenerative disorders. This disease is mainly characterized by tremor, bradykinesia, rigidity and postural instability that results primarily from a loss of dopaminergic neurons of nigrostriatal pathway. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is well known to damage the nigrostriatal dopaminergic pathway as seen in Parkinson's disease. Recent evidence shows that glial-related response plays a key role in the MPTP neurotoxic process and the blockade of glial activation may be a new therapeutic approach, which has applicability for Parkinson's disease. On the other hand, dopamine transporters (DAT) are important to the appearance of MPTP neurotoxicity because to be neurotoxin, an MPTP metabolite must first gain access to the dopaminergic neurons via DAT. Several studies suggest that DAT is a mandatory factor for expression of MPTP neurotoxicity and may explain the selective neuronal damage in the substantia nigra in MPTP toxicity. Therefore, DAT is thought to play an important role in the MPTP neurotoxic process and specific blockade of DAT with high-affinity inhibitors in neurodegenerative diseases such as Parkinson's disease, where the effective levels of dopamine are markedly reduced, may have beneficial consequences. In view of these new insights, this article suggests that the overexpression of S100beta protein secreted by glial cells may be an exacerbating factor in the neurodegeneration of dopaminergic cells. In this review, we also demonstrate the possible role of DAT in the brain cells in MPTP neurotoxicity. Thus this review provides valuable information for progressive neurodegeneration of the nigrostriatal dopaminergic neuronal pathway.
Similar articles
- Tyrosine hydroxylase and dopamine transporter expression following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of the mouse nigrostriatal pathway.
Jakowec MW, Nixon K, Hogg E, McNeill T, Petzinger GM. Jakowec MW, et al. J Neurosci Res. 2004 May 15;76(4):539-50. doi: 10.1002/jnr.20114. J Neurosci Res. 2004. PMID: 15114626 - Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.
Teng X, Sakai T, Liu L, Sakai R, Kaji R, Fukui K. Teng X, et al. J Neurochem. 2006 May;97(4):1126-35. doi: 10.1111/j.1471-4159.2006.03833.x. J Neurochem. 2006. PMID: 16686692 - alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
Sidhu A, Wersinger C, Vernier P. Sidhu A, et al. FEBS Lett. 2004 May 7;565(1-3):1-5. doi: 10.1016/j.febslet.2004.03.063. FEBS Lett. 2004. PMID: 15135042 Review.
Cited by
- Revisiting the Role of Astrocytic MAOB in Parkinson's Disease.
Nam MH, Sa M, Ju YH, Park MG, Lee CJ. Nam MH, et al. Int J Mol Sci. 2022 Apr 18;23(8):4453. doi: 10.3390/ijms23084453. Int J Mol Sci. 2022. PMID: 35457272 Free PMC article. Review. - UPRmt activation protects against MPP+-induced toxicity in a cell culture model of Parkinson's disease.
Hu D, Liu Z, Qi X. Hu D, et al. Biochem Biophys Res Commun. 2021 Sep 10;569:17-22. doi: 10.1016/j.bbrc.2021.06.079. Epub 2021 Jun 30. Biochem Biophys Res Commun. 2021. PMID: 34216993 Free PMC article. - Neuroprotective and neurogenic effects of novel tetramethylpyrazine derivative T-006 in Parkinson's disease models through activating the MEF2-PGC1α and BDNF/CREB pathways.
Chen H, Cao J, Zha L, Wang P, Liu Z, Guo B, Zhang G, Sun Y, Zhang Z, Wang Y. Chen H, et al. Aging (Albany NY). 2020 Jul 24;12(14):14897-14917. doi: 10.18632/aging.103551. Epub 2020 Jul 24. Aging (Albany NY). 2020. PMID: 32710729 Free PMC article. - Rifampicin and Parkinson's disease.
Bi W, Zhu L, Jing X, Liang Y, Tao E. Bi W, et al. Neurol Sci. 2013 Feb;34(2):137-41. doi: 10.1007/s10072-012-1156-0. Epub 2012 Jul 21. Neurol Sci. 2013. PMID: 22821065 Review. - Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies.
Ma L, Gholam Azad M, Dharmasivam M, Richardson V, Quinn RJ, Feng Y, Pountney DL, Tonissen KF, Mellick GD, Yanatori I, Richardson DR. Ma L, et al. Redox Biol. 2021 May;41:101896. doi: 10.1016/j.redox.2021.101896. Epub 2021 Feb 14. Redox Biol. 2021. PMID: 33799121 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources